Mitchell Clark, MD, MPH
Assistant Professor of Obstetrics, Gynecology & Reproductive SciencesCards
About
Research
Publications
2025
A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Mcnamara B, Papatla K, Kailasam A, Azodi M, Buza N, Clark M, Hui P, Altwerger G, Dottino P, Ratner E, Bellone S. A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER. International Journal Of Gynecological Cancer 2025, 35: 102143. DOI: 10.1016/j.ijgc.2025.102143.Peer-Reviewed Original ResearchPostmenopausal bleeding: Association of initial place of care with stage at diagnosis for uterine cancer
Xu X, Chen L, Nunez-Smith M, Clark M, Ferris J, Huang Y, Hershman D, Wright J. Postmenopausal bleeding: Association of initial place of care with stage at diagnosis for uterine cancer. Gynecologic Oncology 2025, 203: 75-83. PMID: 41166984, PMCID: PMC12710999, DOI: 10.1016/j.ygyno.2025.10.015.Peer-Reviewed Original ResearchConceptsPostmenopausal bleedingUterine cancerOffice visitsED visitsEmergency departmentMean ageEnd-Results-Medicare databaseUterine cancer diagnosisMean ages of patientsAge of patientsAdvanced uterine cancerDuration to diagnosisAdvanced stage cancerEvaluation of symptomsNon-HispanicCancer diagnosisCareCancer stagePatient characteristicsStage cancerEarly diagnosisRoutine screeningPatientsVisitsCancerDiagnostic Evaluation for Abnormal Uterine Bleeding at Emergency Departments in the United States
Huang W, Ma X, Clark M, Xu X. Diagnostic Evaluation for Abnormal Uterine Bleeding at Emergency Departments in the United States. Women's Health Issues 2025, 35: 306-313. PMID: 40897603, DOI: 10.1016/j.whi.2025.07.008.Peer-Reviewed Original ResearchNon-Hispanic white patientsNon-Hispanic black patientsFollow-up consultationsEmergency departmentAbnormal uterine bleedingWhite patientsNational sample of emergency departmentsNational Hospital Ambulatory Medical Care Survey dataSample of emergency departmentNational sampleBlack patientsAssociation of raceNon-metropolitan areasMultivariate logistic regressionDiagnostic evaluationUterine bleedingReferral/follow-upED visitsPatient/provider characteristicsConsultant physiciansHispanic patientsOutcome measuresWomen ageCancer diagnosisMultivariate regression analysisIn vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma
Greenman M, Hartwich T, Demirkiran C, Bellone S, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. In vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma. Gynecologic Oncology 2025, 200: 318. DOI: 10.1016/j.ygyno.2025.04.452.Peer-Reviewed Original ResearchDatopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma
Greenman M, Demirkiran C, Bellone S, Ettorre V, Hartwich T, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. Datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma. Gynecologic Oncology 2025, 200: 204. DOI: 10.1016/j.ygyno.2025.04.263.Peer-Reviewed Original ResearchRole of systematic lymphadenectomy at the time of cytoreductive surgery among non-high grade serous epithelial ovarian cancers
Greenman M, Demirkiran C, McNamara B, Altwerger G, Ratner E, Santin A, Papatla K, Dottino P, Azodi M, Schwartz P, Clark M. Role of systematic lymphadenectomy at the time of cytoreductive surgery among non-high grade serous epithelial ovarian cancers. Gynecologic Oncology 2025, 200: 239-240. DOI: 10.1016/j.ygyno.2025.04.320.Peer-Reviewed Original ResearchRetrospective analysis of lenvatinib and pembrolizumab in endometrial cancer: Efficacy by tumor characteristics, platinum status and lenvatinib dose
Abozenah Y, Dzienny A, Yamartino K, Pan E, Vlamis C, Azodi M, Ratner E, Santin A, Clark M, Papatla K, Schwartz P, Altwerger G. Retrospective analysis of lenvatinib and pembrolizumab in endometrial cancer: Efficacy by tumor characteristics, platinum status and lenvatinib dose. Gynecologic Oncology 2025, 200: 202. DOI: 10.1016/j.ygyno.2025.04.260.Peer-Reviewed Original ResearchClinical Aspects of Gestational Trophoblastic Disease
Clark M, Ratner E, Schwartz P. Clinical Aspects of Gestational Trophoblastic Disease. 2025, 253-260. DOI: 10.1007/978-3-031-83545-2_15.Peer-Reviewed Original ResearchMolar pregnancyRefractory to initial treatmentIntermediate trophoblastic tumorInvasive molar pregnancyGestational trophoblastic diseaseComplex clinical scenariosRate of regressionTrophoblastic tumorTrophoblastic diseasePrompt diagnosisInitial treatmentClinical entityClinical scenariosPregnancyCenters of excellenceDiseaseChoriocarcinomaImmunotherapySurgeryTumorDiagnosis
2024
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.Peer-Reviewed Original ResearchDiagnostic experiences of Black and White patients with uterine cancer: A qualitative study
Britton M, Izampuye E, Clark M, Ornstein R, Nunez-Smith M, Wright J, Xu X. Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study. Gynecologic Oncology 2024, 191: 67-73. PMID: 39362045, PMCID: PMC11637892, DOI: 10.1016/j.ygyno.2024.09.010.Peer-Reviewed Original ResearchDiagnosis of uterine cancerUterine cancerRacial disparitiesHealthcare systemSocial determinants of healthNon-Hispanic White (WhiteGynecologic careDeterminants of healthDiscriminatory experiencesSemi-structured interviewsPatient engagementSocial determinantsAcceptance of discomfortHealthcare accessPerceived BarriersPatient experienceThematic analysisDiagnostic journeyQualitative studyAudio-recordedBlack respondentsWhite patientsNegative experiencesHealthcareStage II-IV disease
Academic Achievements & Community Involvement
Clinical Care
Overview
Mitchell Clark, MD, is a gynecologic oncologist with training in both surgical and medical oncology. He has expertise in chemotherapy, targeted therapies, and minimally invasive surgeries. He sees women with gynecologic malignancies and complex surgical problems, as well as genetic conditions that put them at risk for developing a gynecologic cancer.
Dr. Clark grew up in a small, rural community, where he began thinking about becoming a doctor after a close family member died from ovarian cancer. “I saw the lack of resources and advanced treatment options, and limitations in the system,” he says. “I was inspired to pursue a specialty where I could advocate for women to receive the highest quality of care close to home.”
Since then he’s seen improvements in both treatments and survival rates for women with gynecologic cancers. Surgery has evolved to the point where he can usually offer a minimally invasive approach that not only treats cancer, but also allows patients to return to their normal routines “faster than ever,” he says. “Being at Yale allows me to offer comprehensive cancer care that encompasses a multidisciplinary approach spanning from early detection to survivorship.”
In addition to caring for patients, Dr. Clark is interested in improving care for his patients through research. “I am passionate about leveraging the power of large health care administrative databases that include thousands of women to try and answer the important questions facing our specialty,” he says. Another interest is early detection and prevention of cervical cancer. “We know that most cervical cancers are due to human papillomavirus [HPV] infections, which can be prevented through vaccination,” Dr. Clark says.
Clinical Specialties
Fact Sheets
Peritoneal Cancer
Learn More on Yale MedicineVaginal Cancer
Learn More on Yale MedicineFertility Preservation
Learn More on Yale MedicineGestational Trophoblastic Tumors
Learn More on Yale Medicine
Board Certifications
Gynecologic Oncology
- Certification Organization
- Royal College of Physicians & Surgeons of CANADA
- Original Certification Date
- 2020
Obstetrics & Gynecology
- Certification Organization
- Royal College of Physicians & Surgeons of CANADA
- Original Certification Date
- 2018
Yale Medicine News
News & Links
News
- October 27, 2025Source: Everyday Health (with Dr. Mitchell Clark)
‘Silent Killers’: 5 Cancers You Need to Know About
- September 10, 2025Source: Livestrong.com
How to Manage Endometrial Cancer Treatment Side Effects
- August 20, 2025Source: Woman's World (with Dr. Mitchell Clark)
Ovarian Cancer Symptoms Are Easy To Miss—but a Doctor Says They’re Often There From the Start
- June 23, 2025
2025 OB/GYN Research and Graduation Day
Get In Touch
Contacts
Obstetrics, Gynecology & Reproductive Sciences
PO Box 208063
New Haven, CT 06520
United States
Administrative Support
Locations
Obstetrics, Gynecology & Reproductive Sciences
Academic Office
Farnam Memorial Building
310 Cedar Street, Wing Gynecologic Oncology, Fl 3rd, Ste 328
New Haven, CT 06510
General Information
203.785.4013Fax
203.785.4135Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.